糖尿病患者最佳血糖控制与结直肠腺瘤及癌症风险降低:一项基于人群的队列研究
该研究纳入2005至2013年新诊断的糖尿病患者,采用倾向性评分匹配和竞争风险模型分析基线及随访期间血糖控制与结直肠癌及腺瘤风险的关系。结果显示最佳血糖控制(平均HbA1c<7%)与结直肠癌风险降低相关(SHR 0.72),且风险随HbA1c升高呈阶梯式增加,对左侧结肠和直肠有益,对右侧结肠无显著影响。
要点
- 最佳血糖控制与结直肠癌风险降低相关,SHR 0.72(95%CI 0.65-0.81)。
- 获益限于左侧结肠(SHR 0.71)和直肠(SHR 0.71),右侧结肠无显著差异。
- HbA1c升高与结直肠癌风险呈阶梯式增加(P趋势<0.001)。
核心结论
- 糖尿病患者血糖控制与结肠腺瘤及结直肠癌风险独立相关,且存在生物学梯度。
研究设计与样本
- 基于人群的队列研究,纳入2005至2013年新诊断的糖尿病患者,经倾向性评分匹配后共88 468例,中位随访7.2年。
主要发现
- 匹配队列中1229例(1.4%)发生结直肠癌,中位随访7.2年(IQR 5.5-9.4)。
- 最佳血糖控制与结直肠癌风险降低相关(SHR 0.72;95%CI 0.65-0.81)。
- 获益限于左侧结肠(SHR 0.71;95%CI 0.59-0.85)和直肠(SHR 0.71;95%CI 0.57-0.89),右侧结肠无显著关联(SHR 0.86;95%CI 0.67-1.10)。
- 以基线/随访期间均未达最佳控制为参照,仅随访期间最佳控制SHR 0.79,仅基线最佳控制SHR 0.71,两个时期均最佳控制SHR 0.61。
- 最佳血糖控制与任何、非进展期及进展期结肠腺瘤风险降低相关(SHR 0.73-0.87)。
关键数值与推荐
- 最佳血糖控制定义为基线平均HbA1c<7%。
- HbA1c 7.0%至<7.5%组SHR 1.34,7.5%至<8.0%组SHR 1.30,8.0%至<8.5%组SHR 1.44,≥8.5%组SHR 1.58(P趋势<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Whether varying degrees of glycaemic control impact colonic neoplasm risk in patients with diabetes mellitus (DM) remains uncertain. DESIGN: Patients with newly diagnosed DM were retrieved from 2005 to 2013. Optimal glycaemic control at baseline was defined as mean haemoglobin A1c (HbA1c)<7%. Outcomes of interest included colorectal cancer (CRC) and colonic adenoma development. We used propensity score (PS) matching with competing risk models to estimate subdistribution HRs (SHRs). We further analysed the combined effect of baseline and postbaseline glycaemic control based on time-weighted mean HbA1c during follow-up. RESULTS: Of 88 468 PS-matched patients with DM (mean (SD) age: 61.5 (±11.7) years; male: 47 127 (53.3%)), 1229 (1.4%) patients developed CRC during a median follow-up of 7.2 (IQR: 5.5-9.4) years. Optimal glycaemic control was associated with lower CRC risk (SHR 0.72; 95% CI 0.65 to 0.81). The beneficial effect was limited to left-sided colon (SHR 0.71; 95% CI 0.59 to 0.85) and rectum (SHR 0.71; 95% CI 0.57 to 0.89), but not right-sided colon (SHR 0.86; 95% CI 0.67 to 1.10). Setting suboptimal glycaemic control at baseline/postbaseline as a reference, a decreased CRC risk was found in optimal control at postbaseline (SHR 0.79), baseline (SHR 0.71) and both time periods (SHR 0.61). Similar associations were demonstrated using glycaemic control as a time-varying covariate (HR 0.75). A stepwise greater risk of CRC was found (Ptrend<0.001) with increasing HbA1c (SHRs 1.34, 1.30, 1.44, 1.58 for HbA1c 7.0% to <7.5%, 7.5% to <8.0%, 8.0% to <8.5% and ≥8.5%, respectively). Optimal glycaemic control was associated with a lower risk of any, non-advanced and advanced colonic adenoma (SHRs 0.73-0.87). CONCLUSION: Glycaemic control in patients with DM was independently associated with the risk of colonic adenoma and CRC development with a biological gradient.
引用
- Mao X, Cheung KS, Tan JT, et al. Optimal glycaemic control and the reduced risk of colorectal adenoma and cancer in patients with diabetes: a population-based cohort study. Gut. 2024. PMID: 38569845. doi:10.1136/gutjnl-2023-331701
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。